蒽环类耐药转移性乳腺癌,anthracycline-resistant metastatic breast cancer
1)anthracycline-resistant metastatic breast cancer蒽环类耐药转移性乳腺癌
1.Clinical oncologists should deliver chemotherapy based on evidence-based medicine and standardization for patients withanthracycline-resistant metastatic breast cancer,pay attention to individual treatment,and only this can make a new breakthrough in the treatment of patients with this disease.肿瘤学工作者应以循证医学为指导,合理选择化疗方案,注重个体化治疗,才能在蒽环类耐药转移性乳腺癌的治疗上取得新突破。
英文短句/例句
1.The Present Treatment and Thinking of Anthracycline-resistant Metastatic Breast Cancer蒽环类耐药转移性乳腺癌的治疗现状与思考
2.An analysis on clinical efficacy of vinorelbine combined with gemcitabine for patients with anthracycline-and taxane-refractory metastatic breast cancer长春瑞滨联合吉西他滨治疗蒽环类和紫杉类药物耐药的转移性乳腺癌的临床疗效分析
3.Efficacy and Toxicity of Gemcitabine in Combination with Vinorelbine on Metastatic Breast Cancer;吉西他滨联合长春瑞滨治疗蒽环类和紫杉类耐药的转移性乳腺癌的疗效和安全性评价
4.Clinical Comparison of Gemcitabine Combined Cisplatin Regimen Versus Vinorelbine Combined Cisplatin Regimen as Chemotherapy for Anthracycline-and Taxane-resistant Metastatic Breast CancerGP与NP方案治疗对蒽环类及紫杉类均耐药的转移性乳腺癌的疗效观察
5.Gemcitabine and cisplatin combination chemotherapy as alternative agents for metastatic breast cancer patients with anthracycline and taxane resistance吉西他滨联合顺铂治疗蒽环类及紫杉类耐药转移性乳腺癌的临床观察
6.Docetaxel and Xeloda Combined Chemotherapy in Anthracyclines Resistant Advanced Breast Cancer多西他赛联合希罗达治疗蒽环类耐药性晚期乳腺癌
bination of Gemcitabine and Vinorelbine in the Treatment for 24 Cases of Advanced Breast Cancer with Taxanes/Anthracyclines Resistance吉西他滨联合长春瑞滨治疗蒽环类/紫杉类耐药晚期乳腺癌24例
8.Mitomycin Combined with Cisplatin in the Treatment of 23 Cases with Anthracycline and Taxane-Resistant Advanced Breast Cancer丝裂霉素联合顺铂治疗蒽环类及紫杉类耐药晚期乳腺癌23例
9.Clinical Observation on Gemcitabine Combined with Capecitabine in the Treatment of Anthracyclines-Resistant Breast Cancer吉西他滨联合卡培他滨治疗蒽环类耐药的晚期乳腺癌的临床观察
10.Paclitexal-based combination chemotherapy in the treatment of fourty-six patients with anthracycline-resistant advanced breast cancer紫杉醇为主的联合方案治疗蒽环类耐药的晚期乳腺癌46例
11.Preliminary observation of pemetrexed combined with cisplatin in the treatment after the treatment failure of anthracycline and taxane in advanced metastatic breast cancer培美曲塞联合顺铂方案治疗蒽环类及紫杉类治疗失败的晚期转移性乳腺癌的初步研究
12.Clinical Study of Echocardiography in Assessment of Cardiotoxity in Breast Cancer Patients Treated with Anthracycline;超声心动图评价蒽环类药对乳腺癌患者心脏毒性的临床研究
13.Relation of expression of survivin and BCRP gene in prediction of response to chemotherapy in metastatic breast cancer生存素和乳腺癌耐药蛋白表达与转移性乳腺癌化疗效应的相关性
14.Predictive Value of FHL1 in Breast Cancer Neoadjuvant Docetaxel and Anthracycline ChemotherapyFHL1在乳腺癌紫杉联合蒽环类药物新辅助化疗中的预测价值
parative Study of the Combined Chemotherapy with Paclitaxel or Antracycline for Advanced Breast Cancer紫杉醇及蒽环类药物联合化疗治疗晚期乳腺癌的临床观察
16.The Clinical Efficacy of DDP, MIT and CTX on the Treatment of Pleura Metastasis of Breast Cancer顺铂、米托蒽醌及环磷酰胺联合治疗乳腺癌胸膜转移的临床疗效
17.Gemcitabine plus cisplatin for the treatment of drug-resistant metastatic breast cancer吉西他滨联合顺铂治疗耐药转移性乳腺癌的临床观察
18.Gemcitabine Plus Cisplatin for Treatment of 34 Cases with Recurrent Breast Cancer after Anthracycines and/or Taxanes Chemotherapy健择联合顺铂治疗蒽环类和(或)紫杉类化疗后复发性乳腺癌34例
相关短句/例句
Metastatic breast cancer转移性乳腺癌
1.Clinical study of the treatment of metastatic breast cancer by mainly paclitexal combined with chemotherapy.;以紫杉醇为主的联合化疗方案治疗转移性乳腺癌的临床研究
2.Clinical Analysis of a combination of Gemcitabine and Cisplatin on 51 Metastatic Breast Cancer Cases;国产吉西他滨联合顺铂在转移性乳腺癌化疗的临床研究
3.Regimen containing pirarubicin(THP) in treatment of metastatic breast cancer.;含吡喃阿霉素方案治疗转移性乳腺癌
3)anthracycline-resistant蒽环类耐药
1.Paclitaxel and cisplatin in treatment ofanthracycline-resistant advanced breast carcinoma;紫杉醇联合顺铂治疗30例蒽环类耐药性晚期乳腺癌的疗效分析
2.Objective To evaluate the efficacy and toxicity of vinorelbine(NVB) plus cisplatin(DDP) in the treatment ofanthracycline-resistant advanced breast cancer.目的观察长春瑞滨(vinorelbine,NVB)联合顺铂(cisplatin,DDP)组成的NP方案治疗蒽环类耐药晚期乳腺癌患者的疗效和毒副反应。
4)Breast cancer with lung metastasis/drug treatment乳腺癌肺转移/药物疗法
5)breast cancer metastasis乳腺癌转移
1.Try hard to illuminating mechanism of MTA1、BRMS1 operating inbreast cancer metastasis.目的;通过研究MTA1、BRMS1在乳腺癌细胞中表达的相关性及与HDAC活性的关系,力图阐明MTA1、BRMS1在乳腺癌转移中的作用机制。
2.In the previous study, our group has demonstrated that O-GlcNAc plays essencial roles inbreast cancer metastasis; however, the underlying mechanism remains to be unclear.本实验室的前期研究工作已经证明,O-GlcNAc促进小鼠乳腺癌4T1细胞的体外迁移和体内肺转移,但O-GlcNAc调节乳腺癌转移的分子机制还有待系统的研究。
3.The correlation between TBX3 mRNA expression and the clinicopathologic parameters in relation tobreast cancer metastasis was analyzed.将这些总RNA逆转录成cDNA后,利用实时荧光定量PCR的方法检测TBX3基因在这些组织中的表达情况,分析其与乳腺癌转移相关的临床病理参数之间的关系。
6)BCRP乳腺癌耐药蛋白
1.Recently,researches are focussed on the MDR,including P-glycoprotein(Pgp),multidrug resistance-associated protein(MRP),lung resistance-asspcoated protein(LRP),topoisomerase II(TopoII)and breast cancer resistance protein(BCRP).目前,P-糖蛋白(P-glycoprotein,Pgp)、多药耐药相关蛋白(multidrug resistance-associated protein,MRP)、肺耐药相关蛋白(lung re-sistance-associated protein,LRP)、拓扑异构酶II(topoisomeraseII,TopoII)及乳腺癌耐药蛋白(breast cancer resist-ance protein,BCRP),已成为人们研究的热点。
2.Objective To explore the function ofBCRP in ovary cancer and establisment ofBCRP expressing ovary cancer cell line 3AO/BCRP.目的探讨乳腺癌耐药蛋白(BCRP)在卵巢癌中的作用和逆转其介导的MDR,建立表达BCRP的耐药细胞系3AO/BCRP。
3.Objective: To investigate the suppression ofBCRP gene and protein by small interfering RNA (siRNA) and the restoration of sensitivity to chemotherapeutic drugs in multidrug-resistant hepatocellular carcinoma cell line HepG2/ADM.目的:研究小片段RNA干扰对肝癌耐药细胞系HepG2/ADM中乳腺癌耐药蛋白(BCRP)基因及其产物表达的抑制作用和逆转其耐药性的效果。
延伸阅读
乳腺癌乳腺癌breast，cancerof乳房的恶性肿瘤。发病率在中国占全身各种恶性肿瘤的7％～10％，在妇女仅次于宫颈癌。发病年龄以40～60岁居多数，其中又以45～49岁(更年期)和60～64岁为最多。发病原因与性激素变化有很大关系。临床表现：最早的表现为患者侧乳房出现无痛、单发的小肿块，质硬，表面不光滑，与周围组织分界不很清楚，因此无自觉症状，常在洗澡、更衣时无意中发现。癌块增长的速度较快，随其体积增大，侵及周围组织后，在乳房内不易推动，进一步可引起乳房外形改变，如癌块表面皮肤凹陷、乳头牵向癌块方向、乳头内陷等，为重要乳腺癌体征。癌块继续增长，因皮内和皮下淋巴管被癌细胞阻塞引起局部淋巴水肿，故表面皮肤呈暗红色。癌块发展至晚期可侵入胸肋膜、胸肌，以致癌块固定于胸壁而不易推动，并出现疼痛症状，有时皮肤破溃形成溃疡或呈菜花状。乳腺癌的转移途径为淋巴转移，晚期也可有血行转移，最初转移至腋窝淋巴结，先为散在，数目少，质硬无痛，可推动，以后数目增多，互相粘连成团，甚至与皮肤和深部组织粘连。按疾病严重程度分为4期：第一期，癌瘤完全局限于乳房内，其直径＜3厘米，无淋巴结转移；第二期，癌瘤＜5厘米，同侧腋窝有数个散在而能推动的淋巴结；第三期，癌瘤直径＞5厘米，同侧腋窝有一连串融合成块的淋巴结；第四期，癌瘤广泛扩散至皮肤，或与胸肌、胸壁固定，广泛淋巴结转移或有远处转移。乳腺癌的预后：Ⅰ期5年治愈率90％左右，但此阶段应用现有的检查方法常常难以与乳房良性肿瘤区分，而活体组织切片检查则可以确诊。故强调开展普查，发现早期病例，或自己发现乳房有肿块时立即就诊。乳腺癌的治疗仍以早期手术治疗为主，辅以放射、激素、化学治疗等。浸润性乳腺癌
